ClinicalTrials.gg
CompletedNCT01988896Updated Dec 17, 2019

Study of Atezolizumab in Combination With Cobimetinib in Participants With Locally Advanced or Metastatic Solid Tumors

A Phase 1 interventional study of Atezolizumab and Cobimetinib in Solid Tumors, sponsored by Hoffmann-La Roche. Completed at 21 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-12-17.

Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Nov 2019, 7 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
153
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a Phase Ib, open-label, multicenter study designed to assess the safety, tolerability, and pharmacokinetics of coadministration of intravenous (IV) dosing of atezolizumab (an engineered anti-programmed death-ligand 1 [anti-PD-L1] antibody) and oral dosing of cobimetinib in participants with metastatic or locally advanced cancer for which no standard therapy exists.

02

Conditions studied

  • Solid Tumors
03

In context

Lead sponsor

Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.

Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Solid tumor that is , locally advanced or recurrent
  • (ECOG) performance status of 0 or 1
  • greater than or equal to (>/=) 12 weeks
  • , as defined by v 1.1
  • Adequate hematologic and end organ function
  • Use of highly effective
  • Histological tumor tissue specimen
  • Participants enrolling in the indication-specific expansion cohorts in Stage 2 must consent to tumor and must have one of the following types of cancer:

    • Metatastic colorectal cancer
    • Non-small cell lung cancer
    • Melanoma

Exclusion Criteria:

Cancer-Specific Exclusion Criteria:

  • Any approved anti-cancer therapy, including chemotherapy, or hormonal therapy within 3 weeks prior to initiation of study treatment
  • Treatment with any other agent or participation in another clinical trial with therapeutic intent within 28 days prior to enrollment
  • Known active or untreated central nervous system (CNS) metastases
  • Uncontrolled tumor-related pain or uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent (once monthly or more frequently) drainage procedures
  • Uncontrolled hypercalcemia or symptomatic hypercalcemia requiring continued use of bisphosphonate therapy or denosumab

General Medical Exclusion Criteria:

  • Pregnant and lactating women
  • History of severe allergic, anaphylactic, or other reactions to chimeric or humanized antibodies or fusion proteins
  • Known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cell or any component of the atezolizumab formulation
  • History of disease
  • Participants with prior allogeneic stem cell or solid organ transplantation
  • Positive test for (HIV)
  • Participants with active , , or tuberculosis
  • Severe infections within 4 weeks prior to Cycle 1 Day 1
  • Signs or symptoms of infection within 2 weeks prior to Cycle 1 Day 1
  • Received therapeutic oral or IV antibiotics within 2 weeks prior to Cycle 1 Day 1
  • Significant cardiovascular disease
  • Major surgical procedure other than for diagnosis within 28 days prior to Cycle 1 Day 1 or anticipation of need for a major surgical procedure during the course of the study
  • Administration of a live, attenuated vaccine within 4 weeks before Cycle 1 Day 1

Exclusion Criteria Unique to Cobimetinib:

  • History of prior significant toxicity from another mitogen-activated protein kinase (MEK) pathway inhibitor requiring discontinuation of treatment
  • Allergy or hypersensitivity to components of the cobimetinib formulations
  • History of congenital long syndrome or corrected QT interval (QTc) greater than (>) 450 milliseconds at screening
  • (LVEF) below institutional lower limit of normal (LLN) or below 50%, whichever is lower, as determined by echocardiogram or Multi Gated Acquisition Scan (MUGA) scan
  • History of or evidence of retinal pathology on ophthalmologic examination that is considered a risk factor for neurosensory retinal detachment, central serous chorioretinopathy (CSCR), retinal vein occlusion (RVO), or neovascular macular degeneration
  • History of malabsorption syndrome or other condition that would interfere with enteral absorption

Exclusion Criteria Related to Medications:

  • Prior treatment with clusters of differentiation (CD) 137 agonists or immune checkpoint blockade therapies, systemic immunostimulatory agents, or systemic medications
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
153 participants (actual)

Study arms

  • Experimental
    Dose-Escalation: Cobimetinib, Atezolizumab

    Participants will receive single dose of 800 milligrams (mg) of atezolizumab IV infusion on Day 1, 15 and 29 of Cycle 1 (cycle length=42 days \[14-day run-in period + 28-day concomitant dosing period\]), thereafter with atezolizumab IV dosing every 2 weeks (q2w) in all subsequent treatment cycles (28 days each). Combination with cobimetinib will begin on Cycle 1 Day 15 and will be given at increasing dose levels during Stage 1. During Stage 1, cobimetinib will be administered once daily (QD) orally for 21 consecutive days out of 28 days (21/7 dosing schedule) at a starting dose of 20 mg with escalation of 20 mg until the maximum tolerated dose (MTD; not more than 60 mg) for the two-drug combination.

    Drug: Atezolizumab · Drug: Cobimetinib

  • Experimental
    Dose-Expansion: Cobimetinib, Atezolizumab

    Participants will receive single dose of 800 mg of atezolizumab IV infusion q2w in all subsequent treatment cycles (28 days each). Participants will receive cobimetinib at the selected recommended RP2D on Days 1-14 of each 28-day cycle during Stage 2.

    Drug: Atezolizumab · Drug: Cobimetinib

Interventions

  • Atezolizumab will be administered at a fixed dose as specified via IV infusion.

    Also known as: MPDL3280

  • Cobimetinib will be administered orally at an escalating dose during Stage 1 and at RP2D during Stage 2.

    Also known as: GDC-0973

06

What researchers measure

Primary outcomes

  1. Phase I: Percentage of Participants With Dose-Limiting Toxicities (DLTs)

    Time frame: Day 15 to Day 42 of Cycle 1 (cycle length=42 days) of dose-escalation phase

  2. Phase I: Maximum Tolerated Dose of Cobimetinib

    Time frame: Day 15 to Day 42 of Cycle 1 (cycle length=42 days) of dose-escalation phase

  3. Phase I: Recommended Phase II Dose of Cobimetinib when Combined with Atezolizumab

    Time frame: Day 15 to Day 42 of Cycle 1 (cycle length=42 days) of dose-escalation phase

Secondary outcomes

  1. Percentage of Participants With Anti-Therapeutic Antibody (ATA) Response to Azetolizumab

    Time frame: Pre-infusion (Hour 0) on Day 1 of Cycles 1, 2, 3, 4, 8 (cycle length=42 days for Cycle 1; 28 days for subsequent cycles) and at treatment completion visit (up to approximately 3.5 years)

  2. Percentage of Participants With Adverse Events (AEs) or Serious AEs (SAEs)

    Time frame: Baseline up to approximately 3.5 years

  3. Serum Maximum Concentration (Cmax) of Atezolizumab

    Time frame: Pre-infusion (Hour 0) on Day 1 of Cycles 2, 3, 4, 8 (cycle length=28 days) and at treatment completion visit (up to approximately 3.5 years); 30 minutes post-infusion (duration=60 minutes) on Cycle 1 Day 1 (cycle length=42 days)

  4. Serum Minimum Concentration (Cmin) of Atezolizumab

    Time frame: Pre-infusion (Hour 0) on Day 1 of Cycles 2, 3, 4, 8 (cycle length=28 days) and at treatment completion visit (up to approximately 3.5 years)

  5. Plasma Cmax of Cobimetinib

    Time frame: Pre-dose (Hour 0) and Hours 2, 4, 6 post-dose on Day 29 of Cycle 1 (cycle length=42 days) and Day 15 of Cycle 2 (cycle length=28 days)

  6. Plasma Cmin of Cobimetinib

    Time frame: Pre-dose (Hour 0) on Day 29 of Cycle 1 (cycle length=42 days) and Day 15 of Cycle 2 (cycle length=28 days)

  7. Area Under the Concentration-Time Curve (AUC) of Cobimetinib

    Time frame: Pre-dose (Hour 0) and Hours 2, 4, 6 post-dose on Day 29 of Cycle 1 (cycle length=42 days) and Day 15 of Cycle 2 (cycle length=28 days)

  8. Percentage of Participants With Best Overall Response, as Determined by Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1

    Baseline up to 3.5 years (assessed at Baseline then every 8 weeks for the first 48 weeks following Day 1 of Cycle 1 \[cycle length=42 days\]; thereafter every 12 weeks until progressive disease \[PD\] or death due to any cause, whichever occurs first \[up to approximately 3.5 years\])

    Time frame: Baseline up to 3.5 years (detailed time frame is provided in the description)

  9. Percentage of Participants With Objective Response (OR; Confirmed Complete Response or Partial Response) as Assessed by Investigator Using RECIST v1.1

    Time frame: Baseline up to 3.5 years (assessed at Baseline then every 8 weeks for the first 48 weeks following Day 1 Cycle 1 [cycle length=42 days]; thereafter every 12 weeks until PD or death due to any cause, whichever occurs first [up to approximately 3.5 years])

  10. Duration of OR, as Determined by Investigator Using RECIST v1.1

    Time frame: Baseline up to 3.5 years (assessed at Baseline then every 8 weeks for the first 48 weeks following Day 1 Cycle 1 [cycle length=42 days]; thereafter every 12 weeks until PD or death due to any cause, whichever occurs first [up to approximately 3.5 years])

  11. Progression-Free Survival (PFS), as Determined by Investigator Using RECIST v1.1

    Time frame: Baseline up to 3.5 years (assessed at Baseline then every 8 weeks for the first 48 weeks following Day 1 Cycle 1 [cycle length=42 days]; thereafter every 12 weeks until PD or death due to any cause, whichever occurs first [up to approximately 3.5 years])

  12. Overall Survival (OS)

    Time frame: Baseline up to death due to any cause (up to approximately 3.5 years)

07

Study locations

21 sites
  • Stanford University Medical Center
    Palo Alto, California 94304, United States
  • Rocky Mountain Cancer Center - Denver
    Denver, Colorado 80220, United States
  • Yale University School Of Medicine
    New Haven, Connecticut 06510, United States
  • Massachusets General Hospital Clinical Trial Network and Institute
    Boston, Massachusetts 02114, United States
  • Beth Israel Deaconess Med Ctr; Neurology/MS Center
    Boston, Massachusetts 02215, United States
  • Sloan Kettering Cancer Center; Pediatric Hematology/Oncology
    New York, New York 10065, United States
  • UNC Lineberger Comprehensive Cancer Center
    Chapel Hill, North Carolina 27514, United States
  • Compass Oncology
    Portland, Oregon 97225, United States
  • SCRI-Tennessee Oncology
    Nashville, Tennessee 37203, United States
  • Texas Oncology, P.A.
    Arlington, Texas 76012, United States
  • University of Washington Seattle Cancer Care Alliance
    Seattle, Washington 98195, United States
  • Peter MacCallum Cancer Centre-East Melbourne
    Melbourne, Victoria 3000, Australia
  • Royal Melbourne Hospital
    Parkville, Victoria 3050, Australia
  • Princess Margaret Hospital; Department of Med Oncology
    Toronto, Ontario M5G 2M9, Canada
  • CHUM Hôpital Notre-Dame
    Montreal, Quebec H2L 4M1, Canada
  • Jewish General Hospital
    Montreal, Quebec H3T 1E2, Canada
  • Universitätsklinikum "Carl Gustav Carus" der Technischen Universität Dresden
    Dresden, 01307, Germany
  • Universitaetsklinikum Freiburg
    Freiburg, 79106, Germany
  • Seoul National University Hospital
    Seoul, 03080, Korea, Republic of
  • Asan Medical Center - Oncology
    Seoul, 05505, Korea, Republic of
  • National University Hospital; Cancer Center
    Singapore, 119074, Singapore
08

References and documents

Publications

  • Hellmann MD, Kim TW, Lee CB, Goh BC, Miller WH Jr, Oh DY, Jamal R, Chee CE, Chow LQM, Gainor JF, Desai J, Solomon BJ, Das Thakur M, Pitcher B, Foster P, Hernandez G, Wongchenko MJ, Cha E, Bang YJ, Siu LL, Bendell J. Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors. Ann Oncol. 2019 Jul 1;30(7):1134-1142. doi: 10.1093/annonc/mdz113. PubMed 30918950 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2013 to primary completion in Nov 2019, 70 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2013
First posted
Nov 20, 2013
StartActual
Dec 27, 2013
Primary completionActual
Nov 4, 2019
CompletionActual
Nov 4, 2019
Last update
Dec 17, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01988896
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Nov 20, 2013
Start date
Dec 27, 2013
Primary completion
Nov 4, 2019
Completion
Nov 4, 2019
Last update
Dec 17, 2019

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Atezolizumab · Cobimetinib

Start the discussion